# Peginterferon Alfa-2a and Ribavirin for Genotype 2 Chronic Hepatitis C: Duration and Ribavirin Dose Stratified by RVR

> **NCT00532701** · PHASE4 · COMPLETED · sponsor: **National Taiwan University Hospital** · enrollment: 880 (actual)

## Conditions studied

- Chronic Hepatitis C

## Interventions

- **DRUG:** Peg-IFN + WB RBV for 16 weeks
- **DRUG:** Peg-IFN + LD RBV for 16 weeks
- **DRUG:** Peg-IFN + WB RBV for 24 weeks
- **DRUG:** Peg-IFN + WB RBV for 48 weeks
- **DRUG:** Peg-IFN + LD RBV for 24 weeks

## Key facts

- **NCT ID:** NCT00532701
- **Lead sponsor:** National Taiwan University Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-11
- **Primary completion:** 2014-03
- **Final completion:** 2014-03
- **Target enrollment:** 880 (ACTUAL)
- **Last updated:** 2014-06-04

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00532701

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00532701, "Peginterferon Alfa-2a and Ribavirin for Genotype 2 Chronic Hepatitis C: Duration and Ribavirin Dose Stratified by RVR". Retrieved via AI Analytics 2026-07-20 from https://api.ai-analytics.org/clinical/NCT00532701. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*